Key result
Left atrial appendage closure with the AMPLATZER cardiac plug was successfully achieved in 95% of patients, with no strokes or deaths occurring over a mean follow-up of 12.7 months.
Why the study?
Does AMPLATZER cardiac plug implantation safely prevent stroke in NVAF patients with contraindications to warfarin?
Observational (n=20)
Yes
Does AMPLATZER cardiac plug implantation safely prevent stroke in NVAF patients with contraindications to warfarin?
LAA closure with the AMPLATZER cardiac plug appears safe and feasible for stroke prevention in an initial Asia-Pacific cohort of NVAF patients with contraindications to warfarin.
No takes yet. Share an insight, caveat, or question.
Supports feasibility in warfarin-contraindicated NVAF; leaves open stroke prevention efficacy in randomized trials.
Lam et al. (2011) conducted an observational in Non-valvular atrial fibrillation (NVAF) (n=20). AMPLATZER cardiac plug (ACP) implantation was evaluated on Successful LAA occlusion. Left atrial appendage closure with the AMPLATZER cardiac plug was successfully achieved in 95% of patients, with no strokes or deaths occurring over a mean follow-up of 12.7 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: